…
IDenta Corp. operates as a detection and forensic science company. The company offers drug, explosives, bullet-hole testing, and phenolphthalein blood detection kits; aero chamber sniffer; and FerroPrint testing products. It provides its solutions to law enforcement, military, and government agencies, as well as other organizations that deal in fighting illicit drugs and terrorist threats. The company has operations in the Israel, United States, the United Nations, DEA, Germany, France, Italy, Spain, Indonesia, Brazil, Mexico, South Africa, Nigeria, Canada, and internationally. IDenta Corp. was founded in 2002 and is headquartered in Jerusalem, Israel.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Identa Corp is an OTCQB-listed company; public filings provide limited detail on its core operations and revenue sources. Long-term growth drivers appear tied to management's strategic plans, potential asset development and clearer disclosure, which may benefit investors if executed and validated.
Material risks include limited public disclosure and regulatory oversight typical of OTC issuers, low liquidity, potential for dilution, and operational and financing uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 0.16M | 0.10M | 0.35M | 0.07M | 0.14M |
| Net income | 0.16M | 0.07M | 0.35M | 0.07M | 0.14M |
| Selling general administrative | 1.00M | 0.85M | 0.60M | 0.52M | 0.44M |
| Gross profit | 0.98M | 1.02M | 0.88M | 0.62M | 0.59M |
| Reconciled depreciation | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M |
| Ebit | - | - | 0.36M | 0.08M | 0.16M |
| Ebitda | 0.20M | 0.14M | 0.38M | 0.08M | 0.16M |
| Operating income | 0.13M | 0.21M | 0.36M | 0.10M | 0.15M |
| Interest expense | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Tax provision | 0.00M | 0.03M | - | - | - |
| Interest income | 0.00M | - | - | - | - |
| Net interest income | -0.01M | -0.01M | -0.01M | -0.01M | -0.01M |
| Total revenue | 1.34M | 1.39M | 1.45M | 1.01M | 0.83M |
| Total operating expenses | 1.21M | 1.18M | 1.09M | 0.91M | 0.68M |
| Cost of revenue | 0.36M | 0.37M | 0.57M | 0.39M | 0.23M |
| Total other income expense net | 0.05M | -0.10M | 0.01M | -0.03M | 0.00M |
| Net income from continuing ops | 0.16M | 0.07M | 0.35M | 0.07M | 0.14M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 1.56M | 1.23M | 1.06M | 0.68M | 0.58M |
| Total liab | 1.10M | 0.80M | 0.72M | 0.69M | 0.59M |
| Total stockholder equity | 0.46M | 0.43M | 0.34M | -0.02M | -0.02M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -3.50M | -3.67M | -3.74M | -4.09M | -4.16M |
| Cash | 0.37M | 0.35M | 0.54M | 0.22M | 0.20M |
| Total current liabilities | 0.63M | 0.70M | 0.61M | 0.64M | 0.54M |
| Net debt | 0.08M | 0.16M | - | 0.32M | 0.27M |
| Short term debt | - | - | - | 0.55M | 0.46M |
| Short long term debt | 0.45M | 0.51M | 0.48M | 0.55M | 0.46M |
| Total current assets | 0.99M | 1.02M | 0.96M | 0.62M | 0.52M |
| Net receivables | 0.15M | 0.21M | 0.09M | 0.06M | 0.09M |
| Inventory | 0.45M | 0.42M | 0.28M | 0.33M | 0.23M |
| Accounts payable | 0.09M | 0.13M | 0.08M | 0.06M | 0.05M |
| Non currrent assets other | - | - | - | 0.05M | 0.05M |
| Non current assets total | 0.57M | 0.21M | 0.10M | 0.05M | 0.05M |
| Capital lease obligations | 0.37M | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.01M | -0.13M | -0.05M | -0.01M | -0.01M |
| Total cash from financing activities | -0.06M | 0.03M | -0.06M | 0.06M | -0.05M |
| Net income | 0.16M | 0.07M | 0.35M | 0.07M | 0.14M |
| Change in cash | 0.02M | -0.19M | 0.32M | 0.03M | 0.09M |
| Begin period cash flow | 0.35M | 0.54M | 0.22M | 0.20M | 0.11M |
| End period cash flow | 0.37M | 0.35M | 0.54M | 0.22M | 0.20M |
| Total cash from operating activities | 0.09M | -0.09M | 0.43M | -0.01M | 0.15M |
| Issuance of capital stock | - | - | - | - | 0.00M |
| Depreciation | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M |
| Change to inventory | -0.03M | -0.14M | 0.05M | -0.09M | -0.03M |
| Change to account receivables | 0.06M | -0.13M | -0.02M | 0.02M | -0.01M |
| Sale purchase of stock | - | - | 0.00M | -0.03M | 0.00M |
| Capital expenditures | 0.03M | 0.13M | 0.05M | 0.01M | 0.01M |
| Change in working capital | 0.04M | -0.19M | 0.01M | -0.06M | -0.01M |
| Other non cash items | 0.00M | 0.01M | 0.05M | -0.04M | 0.00M |
| Free cash flow | 0.06M | -0.22M | 0.38M | -0.03M | 0.14M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IDTA Identa Corp |
- -% |
0.23 | - | - | 0.53 | 2.14 | 0.91 | 5.53 |
| TMO Thermo Fisher Scientific Inc |
0.78 0.11% |
700.22 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
0.86 0.37% |
233.02 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
-0.28 1.14% |
24.63 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-1.12 4.41% |
24.28 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
IDenta Corp. operates as a detection and forensic science company. The company offers drug, explosives, bullet-hole testing, and phenolphthalein blood detection kits; aero chamber sniffer; and FerroPrint testing products. It provides its solutions to law enforcement, military, and government agencies, as well as other organizations that deal in fighting illicit drugs and terrorist threats. The company has operations in the Israel, United States, the United Nations, DEA, Germany, France, Italy, Spain, Indonesia, Brazil, Mexico, South Africa, Nigeria, Canada, and internationally. IDenta Corp. was founded in 2002 and is headquartered in Jerusalem, Israel.
| Name | Title | Year Born |
|---|---|---|
| Mr. Amichai Glattstein | CEO & Director | NA |
| Mr. Baruch Glattstein | Co-Founder & CTO | NA |
| Mr. Mishael Spitzer | Chief Operating Officer | NA |
| Mr. Robert Bianchi | Consultant | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.